EA201290849A1 - Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) - Google Patents

Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)

Info

Publication number
EA201290849A1
EA201290849A1 EA201290849A EA201290849A EA201290849A1 EA 201290849 A1 EA201290849 A1 EA 201290849A1 EA 201290849 A EA201290849 A EA 201290849A EA 201290849 A EA201290849 A EA 201290849A EA 201290849 A1 EA201290849 A1 EA 201290849A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tfpi
monoclonal antibodies
tissue factor
antibodies
antibodies against
Prior art date
Application number
EA201290849A
Other languages
English (en)
Other versions
EA032189B1 (ru
EA032189B9 (ru
Inventor
Петер Шольц
Зуози Ванг
Юнлианг Пан
Ёанна Грудзинска
Кристиан Фотсмайер
Ян Теббе
Йорг Биркенфельд
Нина Вобст
Зимоне Брюкнер
Зузанне Штайниг
Original Assignee
БАЙЕР ХЕЛЬСКЕР ЛЛСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44542552&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290849(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by БАЙЕР ХЕЛЬСКЕР ЛЛСи filed Critical БАЙЕР ХЕЛЬСКЕР ЛЛСи
Publication of EA201290849A1 publication Critical patent/EA201290849A1/ru
Publication of EA032189B1 publication Critical patent/EA032189B1/ru
Publication of EA032189B9 publication Critical patent/EA032189B9/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Abstract

Предоставлены изолированные моноклональные антитела, которые связывают человеческий ингибитор пути тканевого фактора (TFPI). Изобретением также предусмотрены изолированные молекулы нуклеиновой кислоты, кодирующей указанные антитела, связывающие TFPI. Также предоставлены фармацевтические композиции, содержащие анти-TFPI моноклональные антитела, и способы лечения нарушений свертывания крови путем введения указанных антител. Кроме того, настоящее изобретение предоставляет способы получения антител.
EA201290849A 2010-03-01 2011-03-01 Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их EA032189B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30929010P 2010-03-01 2010-03-01
PCT/US2011/026766 WO2011109452A1 (en) 2010-03-01 2011-03-01 Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI)

Publications (3)

Publication Number Publication Date
EA201290849A1 true EA201290849A1 (ru) 2013-05-30
EA032189B1 EA032189B1 (ru) 2019-04-30
EA032189B9 EA032189B9 (ru) 2019-09-30

Family

ID=44542552

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201290849A EA032189B9 (ru) 2010-03-01 2011-03-01 Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
EA201892184A EA201892184A1 (ru) 2010-03-01 2011-03-01 Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201892184A EA201892184A1 (ru) 2010-03-01 2011-03-01 Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора

Country Status (36)

Country Link
US (3) US9309324B2 (ru)
EP (2) EP3345615B1 (ru)
JP (4) JP6025570B2 (ru)
KR (4) KR101974980B1 (ru)
CN (5) CN105001335B (ru)
AU (1) AU2011223710B2 (ru)
BR (1) BR112012022258A2 (ru)
CA (3) CA2976671C (ru)
CL (2) CL2012002415A1 (ru)
CO (1) CO6620068A2 (ru)
CR (1) CR20120453A (ru)
CU (1) CU23982B1 (ru)
CY (2) CY1119410T1 (ru)
DK (2) DK2542257T3 (ru)
DO (1) DOP2012000239A (ru)
EA (2) EA032189B9 (ru)
EC (2) ECSP12012134A (ru)
ES (2) ES2642512T3 (ru)
GT (1) GT201200252A (ru)
HK (2) HK1232232A1 (ru)
HR (2) HRP20171472T1 (ru)
HU (2) HUE047173T2 (ru)
IL (3) IL221551B (ru)
LT (2) LT3345615T (ru)
ME (2) ME03578B (ru)
MX (2) MX2012010198A (ru)
MY (1) MY174760A (ru)
NZ (2) NZ602115A (ru)
PE (1) PE20160538A1 (ru)
PH (3) PH12018500639A1 (ru)
PL (2) PL2542257T3 (ru)
PT (2) PT2542257T (ru)
RS (2) RS56409B1 (ru)
SG (3) SG10201502587SA (ru)
SI (2) SI3345615T1 (ru)
WO (1) WO2011109452A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN102325795B (zh) 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
NZ602115A (en) * 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
TW201212938A (en) * 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
MX2013011218A (es) * 2011-04-01 2013-10-17 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi).
WO2013148248A1 (en) * 2012-03-30 2013-10-03 Bayer Healthcare Llc Protease-regulated antibodies
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US20160009817A1 (en) * 2013-03-15 2016-01-14 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
US9556280B2 (en) * 2013-03-15 2017-01-31 Bayer Healthcare Llc Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics
EA036490B1 (ru) * 2015-02-25 2020-11-17 Могам Инститьют Фор Байомедикал Рисерч Антитела, связывающиеся с tfpi, и содержащая их композиция
SG10201912817YA (en) 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
MX2021004120A (es) * 2018-10-11 2021-09-10 Pfizer Regimen de dosificacion para antagonistas de tfpi.
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技(上海)有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
ES2044941T5 (es) 1987-08-21 1999-02-16 Mallinckrodt Group Inc Estabilizador de hormonas promotoras del crecimiento.
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
EP0417193B1 (en) 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
EP0465513A1 (en) 1989-03-27 1992-01-15 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DE4223132A1 (de) 1992-07-14 1994-01-20 Deutsche Aerospace Verfahren zur Schrittakt-Regeneration bei der Demodulation von digital modulierten Signalen und Anordnung zum Ausführen des Verfahrens
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
JP3698721B2 (ja) 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド 有機溶媒を用いて処理したポリペプチドの賦形剤安定化
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6111079A (en) 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターXa・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
BR9707081A (pt) 1996-01-25 1999-05-25 Schering Ag Soluções de injeção e infusão concentradas aperfeiçoadas para aplicação intravasal
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US20040052799A1 (en) 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
ATE318316T1 (de) 1997-03-26 2006-03-15 Imp College Innovations Ltd In der zellmembran verankertes antikoagulant- fusionsprotein
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
DE59806877D1 (de) 1997-08-21 2003-02-13 Siemens Ag Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
CA2322728A1 (en) 1998-03-12 1999-09-16 Human Genome Sciences, Inc. 31 human secreted proteins
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
HUP0203133A3 (en) 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
JP4623825B2 (ja) 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20020160934A1 (en) 2000-01-14 2002-10-31 Julie Broadus Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
AU2001236005A1 (en) 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
PT1272211E (pt) 2000-04-07 2007-09-14 Signal Coordinating Therapy In Métodos e composições papa tratar neoplasmas
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
NZ522700A (en) 2000-06-16 2006-02-24 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
WO2002011753A1 (fr) 2000-08-04 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Preparations proteiniques a injecter
PT1314437E (pt) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
US7998929B2 (en) 2000-09-01 2011-08-16 Chugai Seikyaku Kabushiki Kaisha Solution preparations stabilized over long time
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
US6912470B2 (en) 2001-05-21 2005-06-28 Ecopia Biosciences, Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
CA2434323A1 (en) 2001-02-07 2002-11-28 Centre National De La Recherche Scientifique (Cnrs) Sequence of the photorhabdus luminescens strain tt01 genome and uses
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6891085B2 (en) 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ,インコーポレイティド IgG抗体の安定な凍結乾燥医薬製剤
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP3665324B2 (ja) * 2001-10-15 2005-06-29 麒麟麦酒株式会社 抗hla−dr抗体
BR0213298A (pt) 2001-10-16 2006-11-07 Rxkinetix Inc formulações com alta concentração de proteìna e processo de fabricação
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2002363253A1 (en) 2001-11-01 2003-05-12 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Igg 항체의 안정한 액상 약학 제형물
WO2003048304A2 (en) 2001-11-29 2003-06-12 Wyeth Holdings Corporation ALLOIOCOCCUS OTITIDIS OPEN READING FRAMES (ORFs) ENCODING POLYPEPTIDE ANTIGENS, IMMUNOGENIC COMPOSITIONS AND USES THEREOF
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
US7452539B2 (en) 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
WO2003065006A2 (en) 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
KR101080021B1 (ko) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
WO2003076575A2 (en) 2002-03-04 2003-09-18 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US7074559B2 (en) 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
AU2005254062B2 (en) 2002-04-11 2011-02-17 Medimmune, Llc High pressure spray-dry of bioactive materials
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2492143A1 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10239073A1 (de) 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
MXPA05003502A (es) 2002-10-08 2005-09-30 Rinat Neuroscience Corp Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo.
KR100542401B1 (ko) 2002-10-23 2006-01-11 한국전자통신연구원 인터넷 차별 서비스 망에서의 연결 수락 제어방법
CA2508214A1 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2853593B1 (en) 2003-03-07 2017-10-04 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and mehods for making and using them
RU2332986C2 (ru) 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
NZ599196A (en) 2003-07-15 2014-01-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
RS53476B (en) 2003-07-18 2014-12-31 Amgen Fremont Inc. Hepatocyte Growth Factor Binders
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
US8496930B2 (en) 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
DE602004026474D1 (de) 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
ES2553987T3 (es) 2003-12-25 2015-12-15 Kyowa Hakko Kirin Co., Ltd. Preparación farmacéutica de base acuosa estable que contiene anticuerpo
EP2287179A3 (en) 2004-01-09 2011-05-18 Novozymes A/S Increased bacillus YweA expression
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
KR101456770B1 (ko) 2004-05-27 2014-10-31 크루셀 홀란드 비.브이. 광견병 바이러스를 중화시킬 수 있는 결합 분자 및 그 용도
WO2006017173A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
CN101151277B (zh) 2005-01-27 2013-11-13 诺维莫尼公司 抗干扰素γ抗体及其使用方法
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AR052469A1 (es) 2005-01-28 2007-03-21 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
CA2598792A1 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
JP2008531692A (ja) 2005-03-04 2008-08-14 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 凝固及び線維素溶解カスケードのモジュレーター
CA2600601A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
US7785595B2 (en) 2005-04-18 2010-08-31 Yeda Research And Development Company Limited Stabilized anti-hepatitis B (HBV) antibody formulations
US7889636B2 (en) 2005-05-24 2011-02-15 Cisco Technology, Inc. System and method for implementing a mid-call policy in a RSVP environment
GB2426887B (en) 2005-06-04 2009-01-07 Ibm Client responsibilities in messaging systems
DK1899462T3 (da) 2005-07-02 2011-06-06 Arecor Ltd Stabile vandige systemer omfattende proteiner
CA2615122A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070086433A1 (en) 2005-10-19 2007-04-19 Cunetto Philip C Methods and apparatus for allocating shared communication resources to outdial communication services
JP5138601B2 (ja) 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
ES2388932T3 (es) 2005-12-02 2012-10-19 Genentech, Inc. Polipéptidos de unión y usos de los mismos
US7669228B2 (en) 2005-12-27 2010-02-23 Cisco Technology, Inc. System and method for changing network behavior based on presence information
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
WO2007112054A2 (en) 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
US20100158925A1 (en) 2006-06-14 2010-06-24 Meera Agarkhed Lyophilized formulations of anti-egfr antibodies
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー/エス 抗nkg2a抗体とその使用
US8355333B2 (en) 2006-08-31 2013-01-15 Ciena Corporation Methods and systems for session initiation protocol control of network equipment
KR20090069330A (ko) 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
CA2671968A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
EP2068923A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
WO2008157356A2 (en) 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2222707B1 (en) * 2007-11-21 2016-01-06 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
PL2222706T5 (pl) 2007-12-14 2017-09-29 Novo Nordisk As Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania
MX2010006395A (es) 2007-12-21 2010-07-01 Hoffmann La Roche Formulacion de anticuerpos.
CA2710775A1 (en) 2007-12-28 2009-07-09 Bioinvent International Ab Formulation
US8268972B2 (en) 2008-02-20 2012-09-18 G2 Inflammation Pty Ltd Humanized anti-C5aR antibodies
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항-인간 인터루킨-20 항체
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN102159204B (zh) 2008-09-19 2015-04-01 辉瑞公司 稳定的液体抗体制剂
CN102301235B (zh) 2008-11-28 2014-11-19 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
KR101977846B1 (ko) 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi 억제제 및 사용 방법
EP2379599B1 (en) 2008-12-22 2015-09-02 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
CN102325795B (zh) 2008-12-22 2015-03-25 诺沃—诺迪斯克有限公司 针对组织因子途径抑制剂的抗体
CA2754528A1 (en) 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation
US20120114646A1 (en) 2009-06-18 2012-05-10 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
EP2473527B1 (en) 2009-09-03 2016-11-30 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
NZ602115A (en) * 2010-03-01 2014-12-24 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated Tfpi阻害剤および使用方法
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
WO2012109675A1 (en) 2011-02-11 2012-08-16 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
MX2013011218A (es) 2011-04-01 2013-10-17 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi).
AU2013235567A1 (en) 2012-03-22 2014-10-09 Baxalta GmbH Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9556280B2 (en) 2013-03-15 2017-01-31 Bayer Healthcare Llc Anti-TFPI antibody variants with differential binding across PH range for improved pharmacokinetics
EA036490B1 (ru) 2015-02-25 2020-11-17 Могам Инститьют Фор Байомедикал Рисерч Антитела, связывающиеся с tfpi, и содержащая их композиция
SG10201912817YA (en) 2015-08-19 2020-02-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof

Also Published As

Publication number Publication date
EA032189B1 (ru) 2019-04-30
PL2542257T3 (pl) 2018-01-31
AU2011223710A1 (en) 2012-09-20
CY1122476T1 (el) 2021-01-27
US9309324B2 (en) 2016-04-12
AU2011223710B2 (en) 2016-04-14
IL277391A (en) 2020-11-30
CN110835373A (zh) 2020-02-25
PH12018500640A1 (en) 2019-07-29
JP6684369B2 (ja) 2020-04-22
JP6475679B2 (ja) 2019-02-27
EA201892184A1 (ru) 2019-03-29
PT2542257T (pt) 2017-10-09
SG183443A1 (en) 2012-09-27
ES2765418T3 (es) 2020-06-09
JP2019089807A (ja) 2019-06-13
CY1119410T1 (el) 2018-03-07
US20120329996A1 (en) 2012-12-27
USRE47150E1 (en) 2018-12-04
IL262444A (en) 2018-12-31
CN102939098B (zh) 2016-08-03
HUE047173T2 (hu) 2020-04-28
KR101903931B1 (ko) 2018-10-02
JP2017035100A (ja) 2017-02-16
NZ602115A (en) 2014-12-24
RS56409B1 (sr) 2018-01-31
DOP2012000239A (es) 2013-08-15
KR20190047135A (ko) 2019-05-07
LT2542257T (lt) 2017-11-27
NZ702494A (en) 2016-09-30
EA032189B9 (ru) 2019-09-30
KR20130004586A (ko) 2013-01-11
IL262444B (en) 2021-01-31
CR20120453A (es) 2013-02-27
SG10201502587SA (en) 2015-06-29
CO6620068A2 (es) 2013-02-15
CU20120126A7 (es) 2013-01-30
GT201200252A (es) 2014-04-03
JP6025570B2 (ja) 2016-11-16
IL221551B (en) 2019-08-29
US20120108796A1 (en) 2012-05-03
CU23982B1 (es) 2014-03-26
BR112012022258A2 (pt) 2016-10-25
KR20170137218A (ko) 2017-12-12
HRP20171472T1 (hr) 2017-12-01
CN105001335B (zh) 2019-10-25
JP2013520996A (ja) 2013-06-10
HK1254947A1 (zh) 2019-08-02
SI2542257T1 (en) 2018-01-31
KR101974980B1 (ko) 2019-05-07
RS59830B1 (sr) 2020-02-28
CL2017003218A1 (es) 2018-06-08
PH12018500639A1 (en) 2019-07-29
SI3345615T1 (sl) 2020-03-31
MX2012010198A (es) 2012-10-03
CA2791685C (en) 2019-07-23
CA2791685A1 (en) 2011-09-09
CA2976671C (en) 2021-01-12
MY174760A (en) 2020-05-13
EP3345615B1 (en) 2019-10-16
EP2542257A1 (en) 2013-01-09
MX354743B (es) 2018-03-16
WO2011109452A1 (en) 2011-09-09
ECSP19025350A (es) 2019-04-30
ES2642512T3 (es) 2017-11-16
CA3101298A1 (en) 2011-09-09
CN106188301A (zh) 2016-12-07
PH12018500641A1 (en) 2019-07-29
JP2020115868A (ja) 2020-08-06
ME03578B (me) 2020-07-20
PE20160538A1 (es) 2016-05-19
CL2012002415A1 (es) 2013-08-23
EP2542257A4 (en) 2013-11-13
CN102939098A (zh) 2013-02-20
CN105001335A (zh) 2015-10-28
CN107987166A (zh) 2018-05-04
HRP20192295T1 (hr) 2020-03-20
EP2542257B1 (en) 2017-07-05
HK1232232A1 (zh) 2018-01-05
PL3345615T3 (pl) 2020-07-13
KR20180091116A (ko) 2018-08-14
DK2542257T3 (en) 2017-10-16
HUE036655T2 (hu) 2018-07-30
SG10201903166PA (en) 2019-05-30
DK3345615T3 (da) 2020-01-20
US8481030B2 (en) 2013-07-09
KR101807894B1 (ko) 2017-12-12
CA2976671A1 (en) 2011-09-09
PT3345615T (pt) 2020-01-17
EP3345615A1 (en) 2018-07-11
ECSP12012134A (es) 2012-09-28
LT3345615T (lt) 2020-02-10
ME02894B (me) 2018-04-20

Similar Documents

Publication Publication Date Title
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
UA107490C2 (ru) TNF-a-СВЯЗУЮЩИЙ БЕЛОК
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
IN2014CN03936A (ru)
MX2009006891A (es) Anticuerpos cd44.
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
EA201590918A1 (ru) Антитела к bmp-6
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
EA202190387A1 (ru) Антитело к cd38 человека и его применение

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU